Skip to site menu Skip to page content

Daily Newsletter

19 October 2023

Daily Newsletter

19 October 2023

Obesity care provider Ilant Health emerges out of stealth

The start-up uses a three-step plan to identify those who would most likely see clinical and financial value from treatment.

October 18 2023

Ilant Health, an obesity treatment company, has launched with $3m in financing, led by healthcare executive Elina Onitskansky.

The company is also backed by Global Medical Response president and CEO Nick Loporcaro; CareBridge, Russell Street Ventures, and Main Street Health chief financial officer (CFO) Brandon Kerns; and Lyra Health CFO Matt Klitus, among others.

It is partnering with employers and health plans to provide individualised and value-based obesity care.

The start-up offers comprehensive care to individuals with obesity, providing evidence-based treatments including surgery, medication, and behavioural therapy through technology and data-driven practices.

It uses a three-step plan to identify those who would most likely see clinical and financial value from treatment. Then, it matches individuals to the treatment most likely to drive outcomes and value and provides an integrated treatment approach for ongoing access to clinical experts.

Besides, Ilant Health is working to make obesity care more affordable and accessible.

Its team is said to include innovators and executives from across the healthcare industry.

Onitskansky said: “Obesity is incredibly complex - it’s a medical problem, a health equity problem, a bias problem, and a cost problem.

“We’re seeing unprecedented increases in conditions and costs associated with obesity - whether that's cardiometabolic diseases, musculoskeletal issues, or obesity-related cancers - and surging demand for high-cost obesity treatments.

“We’re seeing increasing discussions of obesity - even as the biases and the stigma associated with obesity remain incredibly high.

“We need to get away from simple answers to the obesity epidemic and recognise that the solution needs to be as nuanced and multifaceted as the problem we’re facing.”

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close